유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

gen.orph - miglustaattia - gaucherin tauti - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - miglustat gen. orph on tarkoitettu aikuispotilailla, joilla on lievä tai kohtalainen tyypin 1 gaucher-tauti. miglustaatti gen. orph voidaan käyttää vain potilaille, joille entsyymikorvaushoito ei sovi. miglustat gen. orph on tarkoitettu hoitoon progressiivinen neurologiset oireet aikuisilla ja lapsilla, joilla oli niemann-pickin tyypin c tautia.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

astrazeneca ab - natrium zirkonium cyclosilicate - hyperkalemia - kaikki muut terapeuttiset tuotteet - lokelma on tarkoitettu hoitoon hyperkalemia aikuisilla potilailla.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustaattia - gaucherin tauti - muut ruoansulatuskanavan ja aineenvaihduntatuotteet - miglustaatti dipharma on tarkoitettu suun hoito aikuisten lievän ja keskivaikean tyypin 1 gaucher ' n tautia. miglustaatti dipharma voidaan käyttää vain potilaille, joille entsyymikorvaushoito ei sovi. miglustaatti dipharma on tarkoitettu hoitoon progressiivinen neurologiset oireet aikuisilla ja lapsilla, joilla oli niemann-pickin tyypin c tautia.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressantit - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

scipharm sàrl - treprostinil natrium - hypertensio, keuhkokuume - antitromboottiset aineet - treatment of adult patients with who functional class (fc) iii or iv and:inoperable chronic thromboembolic pulmonary hypertension (cteph), orpersistent or recurrent cteph after surgical treatmentto improve exercise capacity.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

orion corporation - pregabaliini - epilepsialääkkeet - kissat - alleviation of acute anxiety and fear associated with transportation and veterinary visits.

유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - aivolisäkkeen ja hypotalamuksen hormonit ja analogit - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.